UNSPSC 51272111: Amethocaine or tetracaine

This classification denotes an anesthetic agent with the molecular formula C15H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0619F35CGV, chemically known as p-(butylamino)benzoic acid, 2-(dimethylamino)ethyl ester but generally known as tetracaine, which bears US NIH Compound Identifier 5411. European Medicines Agency schedules Tetracaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10940MIG.

UNSPSC 51272111 Amethocaine or tetracaine is a Commodity code that maps to local health and pharmaceutical procurement activity, though the recent opportunities posted under this code do not directly reflect purchases of the anesthetic itself. Instead, state and local buying offices are using the code — or related pharmaceutical classification — to solicit broader pharmaceutical supply agreements, including naloxone, over-the-counter products, and direct-to-manufacturer prescription programs. The work being solicited spans emergency-response medications (naloxone and drug deactivation systems), multi-source generic pharmaceuticals distributed through authorized wholesalers, and exploratory procurement for direct pharmacy benefit management arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP, spanning Minnesota and Oregon). The mix suggests that pharmaceutical procurement at the state and local level operates through both direct county-level buys and cooperative purchasing vehicles, with the latter serving as a contracting mechanism for multiple jurisdictions.

Recent activity concentrates in Florida, Texas, and the Minnesota-Oregon corridor. Seminole County posted an IFB (solicitation IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through a two-year contract with one-year renewal option. The Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program, functioning as market intelligence before a formal RFP. MMCAP released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers, with contract effectiveness July 1, 2026, and evaluation weighted heavily toward price competitiveness (75 percent). Cooperative purchasing agreements typically carry two-year terms with optional extensions and require vendors to maintain substantial insurance coverage, EDI capability, and cGMP and DSCSA compliance. The code shows modest but diverse recent activity across health department, state agency, and cooperative purchasing structures.